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Various pharmacological studies have implicated the dopamine D3 receptor as an interesting therapeutic target in the treatment of different
neurological disorders. Because of these putative therapeutic applications, D3 receptor ligands with diverse intrinsic activities have been an active
field of research in recent years. Separation of purely D3-mediated drug effects from effects produced by interactions with similar biogenic amine
receptors allows to verify the therapeutic impact of D3 receptors and to reduce possible side-effects caused by “promiscuous” receptor interactions.
The requirement to gain control of receptor selectivity and in particular subtype selectivity has been a challenging task in rational drug discovery
for quite a few years. In this review, recently developed structural classes of D3 ligands are discussed, which cover a broad spectrum of intrinsic
activities and show interesting selectivities.
© 2006 Elsevier B.V. All rights reserved.Keywords: Dopamine D3 receptor; Agonist; Antagonist; Structure activity relationship; Rational drug discovery; G protein-coupled receptor
Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 871
2. Homology-based difficulty to gain selectivity among D2-like receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 872
3. Recent progress in controlling subtype selectivity and intrinsic activity of D3 ligands . . . . . . . . . . . . . . . . . . . . . . . . 872
3.1. Heterocyclic agonists . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 872
3.2. Non-aromatic agonists . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 875
3.3. 4-Phenylpiperazines and analogs with partial agonistic and antagonistic properties . . . . . . . . . . . . . . . . . . . . . . 876
3.3.1. Modifications of the π1 moiety. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 877
3.3.2. Modifications of the π2 moiety. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 880
3.3.3. Further extensions of the π1 moiety . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 881
3.3.4. 3-Dimensional extensions of the π1 moiety . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 882
3.3.5. Rigidization of the spacer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 884
4. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 885
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 885⁎ Corresponding author. MRC Centre of Protein Engineering, Medical
Research Council Centre, Hills Road, Cambridge, CB2 2QH, UK. Tel.: +44
1223 402044; fax: +44 1223 402140.
E-mail address: fmb@mrc-lmb.cam.ac.uk (F. Boeckler).
0005-2736/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2006.12.0011. Introduction
In more than 15 years of research since the discovery of the
D3 receptor by Sokoloff et al. [1], enormous progress has been
made in improving our understanding of its physiological
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located in brain regions which have an impact on emotional
and cognitive functions, such as e.g. the nucleus accumbens and
the islands of Calleja [2–4], the D3 receptor is capable of
affecting behavioral properties, such as locomotor activity, rein-
forcement and reward. Thus, various pharmacological studies
have investigated the D3 system as an interesting therapeutic
target for the treatment of schizophrenia [5,6], Parkinson's
disease [7], drug-induced dyskinesia [8] and drug abuse (in
particular cocaine addiction) [6,9]. Moreover, D3 might be
involved in the cortical development during gestation obviously
orchestrating neuronal migration and differentiation [10].
Neuroprotective effects during the induction phase of
Parkinson's disease have been reported for D3 receptor agonists,
such as pramipexole (2). Recently, the selective D3 partial
agonist FAUC 329 (30) has been evaluated in the MPTP (1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of
Parkinson's disease [11]. FAUC 329 showed most pronounced
neuroprotective effects on dopamine (DA) depletion in the
nucleus accumbens. reflecting the preferential abundance of D3
receptors in this region [12]. Moreover, it has been demonstrated
that the D3 selective partial agonist BP 897 (27) inhibits cocaine-
seeking behavior caused by the presentation of drug-associated
cues, however, in the absence of any intrinsic, primary
rewarding effects [9]. While D3 agonists have already been
established as valuable treatment alternatives in PD [13,14], the
more recently discovered selective D3 partial agonists and
antagonists are currently evaluated for their clinical relevance.
2. Homology-based difficulty to gain selectivity among
D2-like receptors
Parallel to gaining a more detailed insight into D3 receptor
pharmacology and to the evaluation of respective treatment
opportunities, the available D3 ligands have undergone a
structural evolution: mostly driven by rational drug discovery,
small, dopamine-related agonists have evolved into structurally
diverse agents with high affinity, selectivity over the closely
related biogenic amine receptors and a broad range of intrinsic
activities. However, gaining selectivity for D3 versus the other
D2-like receptors (in particular D2) has been a challenge in
medicinal chemistry for quite a few years. This challenge was
predominantly based on a distinct structural homology between
the D2-like receptors and the absence of direct structural data
about the dopaminergic or even any aminergic receptors.
As outlined in Fig. 1, an elaborate sequence alignment of the
D2-like wild type receptors [15], which is largely consistent
with previous investigations [16,17] reveals a moderate overallFig. 1. Multiple sequence alignment of the D2, D3, and D4 receptors created with
alignment editor GeneDoc [76]. A consensus sequence was generated by applying
consensus level >0.6, ! is any one of the amino acid groups IV, $ is any one of LM
consensus are drawn as white letters on black background, when strictly conserved th
MULTALIGN rules. The transmembrane domains TM1 to TM7 and the adjacen
corresponding to the D3 receptor model depicted above the sequence alignment. Fill
helical structures in a recent comparative modeling study [15]. Cylinder areas without
the dopamine receptor models. Both sequence numbers as well as residue numbers ac
phylogenetic tree illustrates sequence homologies among dopamine receptors.sequence identity between D2 and D4 (∼32%) or D3 and D4
receptors (∼34%). However, the overall sequence identity for
D2 and D3 receptors is significantly higher (∼50%). Extending
the comparison criteria from identity to similarity (as defined by
the use of a Gonnet250 similarity matrix [18]) confirms the
trend observed for identity comparison. The similarity scores
are: 48% for D2/D4, 49% for D3/D4 and 63% for D2/D3.
Focusing on the predicted transmembrane regions as a rough
estimation for the relevant interaction sites for ligand recogni-
tion, sequence identities are increased to 51% for D2/D4, 53%
for D3/D4 and 79% for D2/D3. Representing an analog trend at a
higher level, the sequence similarities for the predicted
transmembrane regions are: 72% for D2/D4, 73% for D3/D4
and 90% for D2 versus D3 receptors. Based on the substantial
sequence homology between D2 and D3 receptors in particular
in the binding-relevant regions, it becomes obvious that the
improvement of D3:D2 selectivity is a challenging task and that
recent success is still hardly explainable on a structural
molecular level.
3. Recent progress in controlling subtype selectivity and
intrinsic activity of D3 ligands
Because of the various putative therapeutic applications, D3
receptor ligands with diverse intrinsic activities have been an
active field of research in recent years. Separation of purely D3-
mediated drug effects from effects produced by interactions with
similar biogenic amine receptors allows to improve the
significance of insights into the therapeutic impact of D3
receptors and to reduce possible side-effects caused by
“promiscuous” receptor interactions. Thus, there is the necessity
to gain control of receptor selectivity and in particular subtype
selectivity, which has been a challenging task in rational drug
discovery for quite a few years. In this review, we present some
recently developed structural families of D3 ligands covering a
broad spectrum of intrinsic activities and showing interesting
selectivities.
3.1. Heterocyclic agonists
Similarity replacement of atoms, functions or moieties based
on physicochemical or topological aspects has lead to numerous
bioisosters of the genuine neurotransmitter dopamine (1). For
instance, exchange of the catechol substructure of DA into a
heterocyclic aminothiazole moiety and rigidization of the
flexible aminoethyl side chain (Scheme 1) has yielded
pramipexole (2), which has become a reference D3 agonist for
in vitro and in vivo studies, as well as a standard therapeuticClustalX [75]. Only marginal manual improvements were necessary using the
standard criteria from MULTALIGN [77]: uppercase is identity, lowercase is
, % is any one of FY, # is any one of NDQEBZ. Residues contributing to this
roughout all 3 sequences, or shaded in gray when conserved in terms of any other
t helix H8 are denoted above the sequences. The cylinders are color-coded
ed areas of the cylinder reflect parts of the sequence, where all 3 receptors show
filling represent parts of the sequence that are found to be helical only in some of
cording to the Ballesteros and Weinstein numbering scheme [78] are given. The
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“gold standard” L-Dopa, pramipexole is frequently used as an
adjunct therapy to reduce L-Dopa doses in later stages of PD or,
particularly, in early-onset patients to delay the begin of L-Dopa
therapy. The D3 affinity of 2 is consistently high (Ki =0.5 to
8.5 nM), but D3:D2-selectivity varies from weak (∼8-fold) to
strong (∼193-fold) [19–21] being largely depended on the assay
conditions. Measured in mitogenesis assay, the intrinsic activity
of pramipexole is ∼100% at D2 and ∼80% at D3 receptors as
compared to the effect of quinpirole [21], which is frequently
used as a reference for full agonism [22] in this functional assay.
The ∼8-fold functional selectivity for D3 (EC50=0.29 nM)
versus D2 receptors (EC50=2.4 nM) is in agreement with
previous studies that reported a ∼15-fold selectivity [19].
Rationalizing that a pyrrole moiety can act as a catechol bio-
isostere as well, a novel series of ligands was constructed by
diversifying the position of the nitrogen throughout the five-Table 1
Binding affinities of regioisomeric azabicyclo[4.3.0]nonanes including 6- and 7-am
aminotetrahydroindoles (6 and 4), 5-aminotetrahydro-pyrazolo[1,5-a]pyridines (12)
Compound Nitrogen position a R a Ki [nM]
bD1
b
(S)-3 e 3a H >100,000
(R)-3 e 3a H >100,000
(S)-4 f 3 H 21,000
(R)-4 f 3 H 42,000
(S)-5 f 2 H 24,000
(R)-5 f 2 H 43,000
(S)-6 f 1 H 35,000
(R)-6 f 1 H 28,000
(S)-7 h 7a H >100,000
(R)-7 i 7a H >100,000
(S)-8 f 1 CH3 16,000
(R)-8 f 1 CH3 16,000
(S)-9 j 1 CHO >20,000
(R)-9 j 1 CHO >20,000
(S)-10 j 7a CHO >20,000
(R)-10 j 7a CHO 47,000
(S)-11 j 7a CN >20,000
(R)-11 j 7a CN >20,000
(S)-12 k 1, 7a H >20,000
(R)-12 k 1, 7a H >20,000
a Corresponding to the depiction in Scheme 2.
b Determined with [3H]SCH23390.
c Determined with [3H]spiperone.
d Determined with the agonist radioligand [3H]pramipexole.
e IC50 [nM] determined in rat brain striatum [23].
f D1 binding determined with porcine D1 receptors [26].
g Ki values of the high and low affinity binding state of the receptor, when analys
h [24].
i Hübner and Gmeiner, unpublished results.
j [25].
k [27].membered aromatic ring. Thus, various regioisomeric azabicy-
clo[4.3.0]nonanes (Table 1, Scheme 2) were generated including
6- and 7-aminotetrahydroindolizines [23–25], 5-aminotetrahy-
droisoindoles and 5- and 6-aminotetrahydroindoles [26]. The
highest affinity for D3 among the unsubstituted derivatives
(R=H) is found for the 1-aza (Ki =38 nM for (S)-6) and 2-aza
analogs (Ki =33 nM for (S)-5), showing both considerable
eutomer:distomer differences to their (R)-enantiomers [26]. In
contrast to (S)-5, a high-affinity binding site for (S)-6 can only be
detected at the D3, but not at the D2 or D4 receptor subtypes.
Comparing the N-methyl (8) or N-formyl (9) with the
unsubstituted (S)-enantiomer of the 1-aza-series (6) indicates
that these substitutions hardly affect D3 receptor binding. It is
notable that (R)-9 exhibits similar affinity for the D3 receptor as
(S)-9 giving an eudismic (eutomer:distomer) ratio of ∼0.9 and
even higher affinities than (S)-9 for the D2 and D4 subtypes.
Despite the weak binding of the unsubstituted 7a-aza derivative
(7) to D3 receptors, introduction of a formyl (10) or cyano
substituent (11) enhances the affinities substantially (Ki =5.3 nM
for (S)-10 also known as FAUC 54 and Ki =7.2 nM (S)-11).
Again, (S)-10 and (S)-11 are clearly the eutomers exhibiting
substantial eudismic ratios of 0.0029 and 0.0026, respectively.
The ∼10-fold preference of FAUC 54 for D3 over D2 receptors
increases by a factor of ∼26 for (S)-11, while the ∼6-foldinotetrahydroindolizines (3 and 7), 5-aminotetrahydroisoindoles (5), 5- and 6-
and analogs at D1, D2, D3, and D4 dopamine receptors
hD2
c DAautorec.
d hD3
c hD4
c
>100,000 6900
72,000 350
27,000 7600 20,000
36,000 9400 14,000
94+11,000 g 33+1100 g 28+2500 g
28,000 3700 5400
12,000 38+1900 g 1700
28,000 2000 3000
4100 150 560
15,000 1500 1650
13,000 34+1800 610
20,000 16,000 3100
230+19,000 g 39+580 g 210+4600 g
58+>20,000 g 45+2500 g 68+5600 g
52+6900 g 21 h 5.3+150 g 32+2500 g
21,000 1700 h 1800
190+6500 g 7.2+140 g 40+9700 g
2800
180+15,000 g 4.0+110 g 58+1700 g
>20,000 2700 13,000
is of the binding data resulted in a biphasic dose–response curve.
Scheme 2.
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both are full agonists at D2 receptors, whereas only FAUC 54
shows near full agonism at D3 (89% relative to quinpirole) and
(S)-11 is a partial agonist (59%). The potencies of these ligands
(EC50=2.4 nM for (S)-11 and EC50=1.1 nM for FAUC 54) are
comparable to quinpirole (EC50=2.6 nM) in this functional
assay. At D4 receptors, FAUC 54 has relatively strong partial
agonistic properties (67%), however, a weak potency (4200 nM)
and (S)-11 is a pure antagonist.
As a very recent extension of this series of ligands, the
aminotetrahydropyrazolo[1,5-a]pyridine 12 was reported [27],
bearing nitrogens in positions 1 and 7a. In this structure, the
hydrogen-bond accepting formyl (10) or cyano functions (11)
are truncated to the lone pair of the sp2-nitrogen. Thus, this
structure can be regarded as a hybrid molecule of FAUC 54
(S)-10 and pramipexole (2). Similar to FAUC 54, 12 shows
substantial D3 affinity and only weak to moderate receptor
binding to D1, D2 and D4. Again, the biological activity and
molecular recognition at the D3 receptor resides exclusively in
the (S)-enantiomer (Ki (high)=4.0 nM). (S)-12 exhibits high
potency (EC50=3.4 nM) and high intrinsic activity (82%) in
stimulation of mitogenesis at D3 receptors.
3.2. Non-aromatic agonists
For the ligands presented in the previous section, the close
relation to the natural ligand DA is still easily visible due to
containing an aromatic system at a set distance from a proto-
natable amine. For quite a long time aromatic or heteroaromatic
substructures have been regarded as an essential pharmacophorerequirement. However, recently several types of non-aromatic,
but conjugated π-systems proved to be able to mimic the
catechol nucleus of DA. This appears to be even more
remarkable, as most of the potent derivatives are lacking any
heteroatomic functions, which could putatively substitute for the
polar hydroxyl functions of DA. While polar hydroxyls of their
equivalents are expected to be involved in receptor binding [28–
30], increasing evidence suggests that optimized hydrophobic
effects can compensate for the attractive forces resulting from
hydrogen bonds (reviewed by [31]).
In the class of conformationally restrained enynes (Scheme 3),
the methyl- (14) and trimethylsilyl-substituted (16) acetylene
derivatives exhibit modest D3 binding (Table 2), while its
unsubstituted analog (13 also known as FAUC 73) has low
nanomolar D3 affinity (5.2 nM) and ∼52-fold preference for D3
over D2 receptors [32,33]. In contrast to these favorable properties
of FAUC 73, several other members of this structural class, such
as the hydroxymethyl-substituted (15) or the phenyl-substituted
acetylenes (17), the nitrile analog (18) and the whole class of
enediynes (19–21) are inactive at the D2-like receptors. Inte-
restingly, none of the ligands with putative hydrogen-bonding
properties (e.g. 15 or 18) shows any significant receptor binding.
Exchanging the acetylene in 13 by a vinyl function produced
the diene FAUC 206 (22), which exhibits notable D3 affinity
(5.6 nM) and preference over D2 (41-fold). Additionally, FAUC
206 displays improved preference of 64-fold for D3 over D4
receptors [33]. Experimental and computational investigations
suggest that the s-trans-isomer should be considerably favored.
The high affinity of FAUC 206 for D3 implies that specific
hydrogen bond-like interactions of the acetylene proton in
Table 2
Binding affinities of non-aromatic D3 ligands including (aza)enynes (13–18),
endiynes (19–21), a diene (22), a dienyne (24) and (aza)endiynes (23 and 25) at
bD1, hD2L, hD3, and hD4.4 dopamine receptors
Compound Ki [nM] Ratio
bD1
a hD2L
b hD3
b hD4.4
b D2/D3 D4/D3
13 c, d >20,000 270+14,000 e 5.2+590 e 22+380 e 52 4.2
14 f 44,000 g 110+16,000 53+2600 4100 2.1 (77)
15 f 38,000 g 16,000 7400 2200 2.2 0.30
16 c >20,000 160+>20,000 47+1600 160+3800 3.4 3.4
17 c >20,000 15,000 3500 16,000 4.3 4.6
18 c >20,000 >20,000 13,000 >20,000 >1.5 >1.5
19 c 16,000 12,000 4400 3900 2.7 0.89
20 c 3900 11,000 2800 1900 3.9 0.68
21 c 2200 5200 1800 1400 2.9 0.27
22f, h 40,000 g 230+12,000 5.6+430 360+3100 41 64
23 i 21,000 g 42+5300 26+910 77+5600 1.6 3.0
24 j 26,000 g 260+9700 9.1+500 250+6100 29 27
25i, k 12,000 g 94+10,000 3.2+49 6.3+420 29 2.0
a Determined with [3H]SCH23390.
b Determined with [3H]spiperone.
c [32].
d Ste
e Kihigh and Kilow values derived from a biphasic curve, if data analysis fitted
better with the equations for a two-site binding mode.
f [33].
g Determined using porcine D1 receptors (pD1), instead of bovine (bD1).
h FAUC 206.
i [34].
j [35].
k FAUC 88.
Scheme 3.
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binding mode of these ligands. Subsequent structure activity
relationship studies focusing on the enlargement of the π-
electronic system, have led to the introduction of a further triple
bond yielding conjugated (aza)endiynes [34]. In addition, a vinyl
substituent was alternatively introduced giving a structure of the
dienyne type (24) [35]. D3 affinity is improved by the different
substituents in the order: cyano (Ki =26 nM for 23)<vinyl
(Ki =9.1 nM for 24)<ethynyl (Ki =3.2 nM for 25). In fact, the
cis-hexendiyne functionality of FAUC 88 (25) is superior to the
butenyne moiety of the lead compound FAUC 73 (13) making it
the most potent non-aromatic dopamine receptor ligand yet
investigated (Table 2). From a comparison of the molecular
electrostatic potentials (Fig. 2), it becomes obvious that the
extended conjugated π-system of FAUC 88 is able to mimic
efficiently the molecular electrostatic potential (MEP) of the
α-rotamer of dopamine.
FAUC 88 is a mixed D3/D4 agonist with only ∼2-fold pre-
ference for D3 over D4, but ∼29-fold preference over D2.
Like FAUC 73, FAUC 88 does not exhibit significant binding
to 5-HT1A (Ki =1000 nM for FAUC 73 and Ki =150 nM for
FAUC 88 using the radioligand [3H]8-OH-DPAT) or 5-HT2
receptors (Ki =9000 nM for FAUC 73 and Ki =3100 nM for
FAUC 88 using the radioligand [3H]ketanserin). Moreover,
both ligands have substantial ligand efficacy (>85% for both
at D2L, 72% for FAUC 88 and 74% for FAUC 73 at D3, and
>60% for both at D4.2) relative to the maximal effect ofquinpirole as determined in mitogenesis assays. Consistent with
affinity values from binding experiments, the potency of FAUC
88 (EC50=3.2 nM) indicates that it has a superior activity profile
compared to FAUC 73 (EC50=4.4 nM).
The high affinities and potencies of compounds presented in
this section indicate that aromatic or heteroaromatic systems,
although being commonly present in DA agonists, appear to be
not essential for molecular recognition or intrinsic activity at the
D3 receptor. Thus, this uncommon (“fancy”) bioisosteric
replacement of the aromatic by conjugated, but non-aromatic
π-systems has proven to be a powerful strategy for the gene-
ration of preferential D3 agonists and could be further exploited
for probing the nature of ligand–receptor complexation between
π-systems.
3.3. 4-Phenylpiperazines and analogs with partial agonistic
and antagonistic properties
During the last decade, 4-phenylpiperazine has been
recognized as a “privileged structure” for biogenic amine
receptors. In particular with respect to the application as potent
and selective D3 ligands, the class of 4-phenylpiperazines and
its close derivatives have become quite popular. Basically, most
of these ligands comprise the following structural features
(Scheme 4): An aromatic or heteroaromatic carboxamide (π1)
that is connected through a conformationally flexible or (partly)
rigidized alkyl-spacer of variable length (spacer) to a piperazine
bearing an aromatic or heteroaromatic moiety in position 4 (π2).
Fig. 2. Isopotential surfaces of dopamine and FAUC 88 contouring negative molecular electrostatic potentials (MEP; −1.0 kcal/mol). To facilitate easier comparison
both molecules are directly superimposed fitting the protonatable amine as their common interaction point.
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nities and functional potencies have been reported involving
some ligands cited in this section. These differences appear to
concern predominantly the measurement of D2 receptor
affinities, whereas D3 affinities are found to be rather consistent.
However, D3:D2 selectivity ratios are of course affected.
Possible underlying reasons for these discrepancies have been
recently discussed [36].
3.3.1. Modifications of the π1 moiety
The 2-methoxyphenylpiperazines GR 103691 (26) and BP
897 (27), as well as the 2,3-dichlorophenylpiperazine NGB
2904 (28) can be regarded as early lead structures of this family
of ligands (Scheme 5). The 4′-acetyl-biphenyl-4-carboxamide
GR 103691 shows subnanomolar D3 affinity (0.32 nM) and
∼130-fold selectivity for D3 versus D2 receptors [37]. Although
the selectivities against the other DA receptors subtypes are
substantial (e.g. ∼1300-fold over D1), distinct affinities for 5-
HT1A (Ki =3.2 nM) and α1 receptors (Ki =13 nM) have been
reported. However, replacement of the 4′-acetyl with a 4′-
methylsulphone or a 4′-amino group improves the D3:5-HT1A
selectivity.
Variation of the arylcarbamide moiety yielded the 9H-
fluoren-3-carboxamide 28 (NGB 2904), a tricyclic D3 receptor
antagonist [38]. High D3 affinity (Ki =1.4 nM), a >160-fold
selectivity for D3 versus all other DA receptor subtypes and
potent antagonism in mitogenesis assays (EC50=5.0 nM) has
been reported for 28. More recently, the 9H-fluorene-9-
carboxamide 29, a less linear regioisomer of 28, has been
synthesized, but showed only a moderate and nonselective
binding profile (Ki =19 nM at D3 and Ki =10 nM at D2) [39].
Particular interest in this ligand family has been sparked by
the discovery that the naphthamide derivative BP 897 (27) can
reduce cocaine-seeking behavior in rats, while it does not
produce reinforcement on its own [9,40]. BP 897 is a high
affinity D3 receptor ligand (Ki =0.92 nM) with proper selectivityScheme 4.(∼66-fold) over D2 receptors, but also moderate affinity for
5-HT1A (84 nM), α1 (60 nM) and α2 receptors (83 nM). The
affinities for 5-HT7, histamine, muscarinic and opiate recep-
tors have been found to be very low or even negligible. Other
investigators [41] report its D3 affinity and selectivity over D2
to be slightly weaker (1.6 nM; ∼38-fold). BP 897 is a partial
agonist at the human D3 receptor measured by the decrease in
forskolin-induced cAMP synthesis (max. effect relative to
quinpirole = 59% and EC50=1 nM) or by stimulating
mitogenesis (max. effect=55% and EC50=3 nM) [9,42].
However, in more recent studies BP 897 has been
characterized as an antagonist, as it potently (pKb=9.43)
inhibits the acidification response of quinpirole, while alone it
has no effect [41]. Moreover, BP 897 does not modify the
basal levels of [35S]GTPγS, whereas the ligand dose-
dependently (IC50=0.31 nM) inhibits the effects of DA
[43]. Mitogenesis as well as microphysiometry experiments
indicate that BP 897 is an antagonist at D2 receptors [9,41].
Based on the lead structures of BP 897 and NGB 2904, more
selective D3 partial agonists and antagonist have been
discovered. As the pyrazolo-[1,5-a]pyridine moiety acts as a
heterocyclic bioisostere of the naphthamide substructure of BP
897, it provides an excellent opportunity for the fine-tuning of
selectivity and intrinsic efficacy [44]. Exploiting all possible
attachment points of the pyrazolo-[1,5-a]pyridine scaffold, six
regioisomeric carboxamides connected to a o-methoxyphenyl-
piperazine through a butyl chain linker have been obtained
(Scheme 6). The resulting D3 affinities (2.8 to 29 nM) increase
in the order of the attachment points at the various positions:
5>2=6>3>4>7. The pyrazolo-[1,5-a]pyridine-2-carboxa-
mide (30 also known as FAUC 329) exhibits the highest
selectivity versus D2 receptors (∼72-fold) in this series and
binds with nanomolar affinity (4.3 nM) to D3 receptors. FAUC
329 has partial agonist activity (52% compared to quinpirole)
and low nanomolar potency (EC50=1.4 nM) in mitogenesis
assays. Throughout this whole series of regioisomers only
moderate affinity is observed for 5-HT1A and α1 receptors.
FAUC 329 exerts neuroprotective effects in the MPTP (1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of
Parkinson's disease, as it dose-dependently attenuates MPTP-
induced DA reduction in the nucleus accumbens [12]. More-
over, FAUC 329 is able to protect in part against DA depletion
Scheme 5.
Scheme 6.
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immunoreactivity in the substantia nigra pars compacta.
A tetramethylene spacer, as compared to the penta-, tri- or
dimethylene spacer, yields superior D3 affinities and selectivities
versus D2 receptors. These data reinforce findings obtained
during early stages of structure–activity relationship investiga-
tions in the class of 4-phenylpiperazines. Replacement of the
pyrazolopyridine moiety by a benzo[b]furan (31 and 32), benzo
[b]thiophene (33 also known as FAUC 346 and 34 also known as
FAUC 365) or a benzo[b]tellurophene ring system (35 and 36)
results in a marked increase in D3 binding (Ki =0.23 nM to
1.5 nM) [44]. What is more, the selectivities for D3 over D2
receptors are considerably enhanced. Thus, the benzo[b]thio-
phene FAUC 365 is one of most selective D3 antagonists,
reported to date. Interestingly, only the o-methoxyphenyl-deri-
vatives (31, 33, 35) exhibit notable affinities at 5-HT1A and α1
receptors, whereas the 2,3-dichlorophenyl-derivatives (32, 34,
36) display reduced 5-HT1A binding and are almost inactive at
5-HT2 or α1 receptors. Except for the o-methoxyphenyl-analogs
31 and 33, all other derivatives (32, 34–36) are full antagonistsin mitogenesis experiments. Thus, FAUC 346 (33) is a high
affinity (Ki =0.23 nM), superpotent (EC50=0.36 nM) and highly
selective D3 partial agonist (∼50% maximal intrinsic activity),
while FAUC 365 (34) is a full antagonist with subnanomolar
affinity (Ki =0.50 nM) and extraordinary subtype selectivity
(∼7200-fold vs. D2). While other laboratories have been able to
corroborate the high D3 affinities of these two ligands (33 and
34), interesting differences in D2 receptor binding have been
reported [45–47]. Similar measuring inconsistencies have also
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discussion at the beginning of Section 3.3). In order to develop
suitable radiopharmaceuticals for investigating the CNS located
dopamine D3 receptors in vivo, 5-iodo derivatives of the benzo
[b]furan and the benzo[b]thiophene have been synthesized as
new [131I]-labeled SPECT (single photon emission computed
tomography) ligands [48]. The most beneficial combination of
D3 affinity (5.7 nM) and selectivity over D2 (∼560-fold) is
ascribed to the 5-iodo-benzo[b]furan containing a 2,3-dichlor-
ophenylpiperazine (37).
Two other very interesting members of these series of
heteroaromatic bioisosteres of BP 897 and NGB 2904, the indol-
2-carboxamide (38) and 6-cyano-indol-2-carboxamide (39),
have been disclosed in the patent literature [49]. Both have
subnanomolar D3 affinity (Ki =0.56 nM for 38 and Ki =0.25 nM
for 39) and high selectivity versus D2 receptors (∼5500-fold for
38 and ∼640-fold for 39). The indole carboxamide 38 also is
more than 1000-fold selective over D1, D2, D4, 5-HT1A and α1
receptors.
Structure–activity studies starting from D4 selective ligands
have also yielded 32, 34 and 38, which all have high D3
affinity and selectivity over other related receptors [45].
Variation of the spacer length again produced the rank order:
butyl>pentyl>propyl>ethyl, which is in agreement with
previous results regarding the optimal spacer length. Variations
of the π2 moiety for the 3-methoxyphenylcarboxamides
revealed that the replacement of the commonly used 2,3-
dichlorophenyl by a 2,3-dimethylphenyl group (40) maintains
D3 affinity and increases selectivity to at least 300-fold over D4,
5-HT1A and α1 receptors. However, the selectivity over D2
receptors is attenuated from 5200-fold for the 2,3-dichlorophe-
nyl to 450-fold for the 2,3-dimethylphenyl derivative. Other
methoxy-substituted compounds obtained by variation of π1 are
the 1-methoxy-2-naphthamide (41) and the 7-methoxybenzo[b]
furan-2-carboxamide analog (42), which exhibit both subnano-
molar D3 affinities (Ki =0.60 nM for 41 and Ki =0.13 nM for 42)
and substantial selectivities over D2, D4, 5-HT1A and α1 (>950-
fold for 41 and >840-fold for 42). It should be noted that in this
preceding study dopamine receptor subtypes from different
species were compared (human D2, rat D3, and human D4.4) and,
thus, it has been argued that selectivities might be influenced by
species differences [36]. 41 and 42 have been recently evaluated
as [11C]-labeled PET ligands [50].
A further series of heteroaromatic BP 897/NGB 2904
bioisosteres has been generated, yielding compounds, such as
43–45 [51]. The 2-indolcarboxamide 43 is closely related to 38,
except that the 2,4-dichlorophenyl replaces the 2,3-dichloro-
phenyl. The 5-chloro-indole-2-carboxamide derivative 44
shows almost the same binding profile as 43, but 44 acts as a
partial agonist in [35S]GTPγS assays, whereas 43 is an anta-
gonist. For 43 a partial reduction of cocaine-seeking behavior
has been observed in rats, while 44 fails to show any effect in this
animal model. Interestingly, the 1,2,3,4-tetrahydropyrazino
[1,2-a]indole-1(2H)-one 45 retains high affinity for D3
(0.87 nM), even though it lacks both the indole-NH and the
carboxamide-NH hydrogen bonding capacity. However, the
selectivity for D3 over other receptors was reduced for 45 (∼52-fold over D2, ∼38-fold over α1, and ∼5.6-fold over 5-HT1A).
Hence, the hydrogen bond donor function of the carboxamides
may have an impact on subtype selectivity, but certainly not on
D3 receptor recognition.
A new series of o-methoxyphenylpiperazine analogs has
been developed by replacing the naphthamide in BP 897 with
(E)-cinnamide derivatives [52]. The iodo-substituted analogs
47–49 possess increased selectivity for D3 over D2 receptors in
comparison to the unsubstituted (E)-cinnamide 46, while they
maintain high D3 affinity. The selectivity increases from 42-fold
(46) to 84-fold for the 2-iodo-cinnamide (47), 130-fold for the
3-iodo-cinnamide (48) and 150-fold for the 4-iodo-cinnamide
(49). The 4-iodo-cinnamide (49 also known as ST 280) exhibits
the best pharmacological profile in this series and thus has been
ascribed to be a promising radioligand candidate. Exploiting the
benzamide structure and some heteroaromatic bioisosteres in
further structural modifications of the π1 moiety has led to the
4-dimethylaminobenzamide derivative 50, the 4-methylsulfa-
nylbenzamide 51 and the 5-bromo-2,3-dimethoxybenzamide 52
[47,53]. All three ligands feature high affinity binding to D3
receptors (Ki =0.8 nM for 50, Ki =0.6 nM for 51, and
Ki =2.1 nM for 52) and a moderate preference for D3 versus
D2 receptors (43-fold for 50, 53-fold for 51, and 28-fold for 52).
While 52 has been reported to bind with appreciable affinity at
σ1 (809 nM) and σ2 receptors (75 nM), 50 and 51 both show
considerable affinity for 5-HT1A receptors (Ki =6.0 nM for 50
and Ki =1.5 nM for 51). Measuring the inhibition of forskolin-
induced adenylyl cyclase activity, 50 has been determined to be
a weak partial agonist (21% of the maximal effect).
As the development of potent and selective positron
emission tomography (PET) tracers for D3 receptors has been
deemed an important step to investigate the role of this receptor
subtype in the pathophysiology of numerous diseases, a series
of [18F]-labeled PET tracers has been synthesized taking
advantage of 4-bromophenyl carboxamide as a lead structure
[54]. When combined with 2-methoxyphenyl as π2 moiety, the
resulting 4-fluorophenyl carboxamide 53 and 6-fluoropyridin-
3-yl carboxamide 55 exhibit nanomolar D3 affinities (4.3 nM
for 53 and 14 nM for 55), while in combination with 2,3-
dichlorophenyl the D3 affinities are further increased (0.53 nM
for the 4-fluorophenyl carboxamide 54 and 1.1 nM for the 6-
fluoropyridin-3-yl carboxamide 56). All of these ligands share a
moderate preference for D3 over D2 receptors (11 to 32-fold),
whereas the 2,3-dichloro substitution pattern clearly enhances
the selectivity for D3 over D4 (83-fold for 54 and 91-fold for
56), 5-HT1A (110-fold for 54 and 25-fold for 56) and α1 (32-
fold for 54 and 15-fold for 56) at least by a factor of 10 as
compared to the 2-methoxy derivatives 53 and 55, respectively.
For the 6-fluoropyridin-3-yl carboxamides 55 and 56 a
significantly higher radiochemical yield (RCY) of >80% has
been reported. Exchange of the carboxamide in 53 and 54 in the
respective sulfonamides 57 and 58 gives a most interesting
insight into the nature of ligand receptor recognition. Upon this
modification the D3 affinity is substantially impaired (49-fold
for 57 and 30-fold for 58), while the D2 affinity is approx-
imately preserved and the D4 affinity is even slightly improved.
This suggests that an extended planar π system might contribute
Scheme 7.
Scheme 8.
880 F. Boeckler, P. Gmeiner / Biochimica et Biophysica Acta 1768 (2007) 871–887more to efficient D3 receptor binding, than hydrogen bonding
capabilities of the carboxamide or sulfonamide can do.
3.3.2. Modifications of the π2 moiety
As a balanced lipophilicity is know to be crucial for drug
bioavailability and permeation of the blood–brain barrier, tuning
of the calculated logP (clogP) by evaluating different π2 moieties
has been performed in a recent study aiming to identify potential
PET radioligands [55]. Based on the 7-methoxybenzo[b]furan-
2-carboxamide derivative 42 bearing a 2,3-dichloro substituted
phenylpiperazine moiety, alternative (hetero)aromatic systems
have been evaluated (59–65, Scheme 7). Replacement of the
2,3-dichloro substitution pattern by a 2-methoxy substituent (59)
leads to a 200-fold attenuated D3 affinity and selectivity
exceeding the regular reduction frequently observed upon this
replacement. Linear prolongation of the π-system by exchange
of the phenyl into a 2-benzoimidazolyl (60) or a 5-methoxy-2-
benzoxazolyl moiety (61) has a fairly detrimental effect on
ligand recognition by the D3 receptor (Ki >8500 nM). Lateral
prolongation of π2 by introduction of a 3-indazolyl (62), 5-
quinoxalinyl (63), 7-methoxy-1-isoquinolinyl (64) or 5-meth-
oxy-2-benzisoxazolyl (65) replacing the phenyl moiety yields
moderate D3 binding (98 nM–260 nM) for all resulting ligands
62–65 and some D3 versus D2 preference for 63–65 (4.6-fold to
7.7-fold). A broader comparison between 2-methoxyphenyl and
5-methoxy-2-benzisoxazolyl as π2 moieties with similar lipo-
philicity (clogP=3.30 or 3.42, respectively) involving 7
different carboxamides reveals that the 2-methoxyphenyl
derivatives show higher D3 affinity, but tend to be less selective
over D2 receptors.
Trying to increase the chemical diversity in D3 ligand design,
a computational 3D database screening strategy has helped to
identify the hexahydropyrazinoquinoline as a rigidized replace-
ment of the phenylpiperazine moiety [17]. The naphthamide
derivative 66 (Scheme 8) binds with a Ki value of 18 nM to D3
receptors and shows 87-fold selectivity over D2-like receptors
(measured in rat brain homogenate using [3H]spiperone), as
well as 44-fold selectivity over D1-like receptors (measured in
rat brain homogenate using [3H]SCH23390) [56]. Based on the
hypothesis that introduction of a methoxy function attached topositions 7 to 10 of the hexahydropyrazinoquinoline core might
be able to form hydrogen bonds toward the conserved serine
residues in TM5, respective structural variations of 66 have
been performed (Scheme 8). Methoxy functions in position 7 or
10 are able to increase both D3 affinity, as well as selectivity
over D2 receptors, whereas a methoxy substituent in position 9
impairs both affinity and selectivity. Interestingly, when
introducing a methoxy group in position 8, the D3 affinity is
considerably decreased, however, the selectivity over D2
receptors increases significantly indicating that this modifica-
tion is far more detrimental for D2 than for D3 receptor binding.
Going beyondmodifications ofπ2, in a recent study the entire
phenylpiperazine has been structurally reduced to the essential
requirements of a basic nitrogen connected to an aryl group
through an aliphatic linker [57]. Higher degrees of rigidity with
varying geometry and hydrogen-bonding capabilities were
introduced to diversify this phenylalkylamine scaffold. Despite
the fact that it has turned out to be not trivial to find a valid
bioisostere for the “privileged structure” phenylpiperazine, two
scaffolds have been retrieved in this study: the 2-aminoindan and
the 1,2,3,4-tetrahydroisoquinoline (Scheme 9). Combining (E)-
cinnamoylcarboxamide with the N-n-propyl-2-aminoindan
results in a nanomolar D3 ligand (67: Ki =8.5 nM) showing a
39-fold preference for D3 over D2 receptors. Exchange to a
naphthylamide (69) yields slightly increased D3 affinity
(Ki =5.7 nM), but at the expense of a reduced preference over
D2 (selectivity 14-fold). The corresponding secondary amine
(68) shows a marked decrease in D2 and D3 affinity by a factor of
Scheme 9.
Scheme 10.
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naphthamide moiety with 1,2,3,4-tetrahydroisoquinoline as the
second identified scaffold yields ST 80 (70). Replacement of the
naphthamide moiety by cinnamide improves the moderate
binding profile of 70 (Ki =98 nM at D3 and Ki =2200 nM at D2)
resulting in a Ki of 12 nM at D3 receptors for 71 (ST 198) and
also an increased 65-fold D3:D2-selectivity ratio. Furthermore,
ST 198 displays >400-fold selectivity over the other dopamine
receptor subtypes and is devoid of intrinsic activity in
mitogenesis experiments [8]. ST 198 has been employed in
pharmacological studies investigating dopamine autoreceptors
in guinea pigs [58] and exhibits attenuation of L-DOPA-induced
dyskinesias in monkeys simultaneous with a deterioration of
PD-like symptoms and ablation of locomotor activity below the
‘on-time’ threshold [8]. Iodination of the para-position of the
(E)-cinnamide leading to the (E)-3-(4-iodophenyl)acryl-deriva-
tive 72 (ST 283) preserves D3 binding (12 nM) and doubles its
selectivity over D2 receptors (130-fold). ST 283 has been
suggested as a useful D3-selective radioligand with putative
applicability in single-photon emission computed tomography
(SPECT) [57].
3.3.3. Further extensions of the π1 moiety
Using a ligand-based virtual screening approach, a ligand
(73) comprising a shortened π1 moiety attached to a 3-
chlorophenylpiperazine though a n-butylene spacer was identi-
fied [59]. In the 3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl (π1)
moiety the aromatic ring is shifted to a lateral position and thus
should fail to mimic the interactions of the “regular” (hetero-)
aromatic substructure (Scheme 10). However, 73 was demon-
strated to retain still a D3 affinity of 40 nM, as well as a 14-fold
preference over D2. Therefore, 73 may indeed be a novel lead
structure representing a distinct mode of interaction.
In contrast to this “truncation” of the π1 moiety in 73,
considerably more efforts have been made to extend it similar to
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(28). Employing a parallel derivatization method the 4-
phenoxyphenyl derivative 74 and the 1-cyclohexylmethyl
derivative 75 have been obtained [60]. Both 74 and 75 exhibit
low nanomolar affinity to D3 receptors (1.6 nM and 2.0 nM,
respectively) and a good selectivity over D2 receptors (140-fold
and 160-fold, respectively). Taking advantage of a click
chemistry based BAL linker, a solid phase supported parallel
synthesis of a focused library of arylcarboxamides has led to the
biphenyl-4-carboxamide 76, which is attached to a 2-chloro-
phenylpiperazine moiety by a tetramethylene spacer [61]. This
compound has subnanomolar affinity for D3 (0.28 nM), a
pronouncedD3:D2-selectivity (460-fold) and it is more than 850-
fold selective over other dopamine receptors. Although having
just a moderate selectivity for D3 over α1 receptors (∼39-fold),
76 shows the best receptor binding profile of this focused library.
Upon introduction of an aza function into the terminal benzene
ring the resulting 4-(2-pyridinyl)-phenylcarboxamide (77) and
4-(3-pyridinyl)-phenylcarboxamide derivative (78) maintain
both subnanomolar D3 receptor binding (Ki =0.50 nM each)
[46]. With a 50-fold preference over D2 receptors 77 only
slightly exceeds the 36-fold D3:D2 preference of its regioisomer
78. In contrast to 76, both ligands bear a 2,3-dichloro
substitution instead of a 2-chloro substituent at the phenyl
ring. Further heterocyclic and heteroaromatic analogs of the
biphenyl carboxamide have been prepared attempting to identify
potent derivatives with improved lipophilicity [55]. In a series
containing 1,2-benzisoxazolyl as π2 moiety, the 4-(4-morpho-
linyl)benzamide 79 and the 4-(1-imidazolyl)benzamide 80 have
been prepared as heterocyclic and heteroaromatic variations.
Both ligands show moderate affinity at D3 receptors (Ki =38 nM
for 79 and Ki =23 nM for 80), as well as moderate preference of
D3 over D2 receptors (>20-fold for 79 and >33-fold for 80).
However, when comparing these ligands with their bend
isomers, the 3-(4-morpholinyl)benzamide 81 and the 3-(1-
imidazolyl)benzamide 82, it is quite obvious that deviations
from a linear arrangement have substantial impact on affinity
and selectivity. For 81 the D3 affinity is decreased by a factor of
37 to a Ki of 1400 nM, while for 82 even a 240-fold reduction of
D3 affinity to 5500 nM is found. At the same time the moderate
preference for D3 over D2 is lost at all in 81 and 82. The 2-
methoxyphenyl derivatives (83 and 84) show higher D3
affinities than their 1,2-benzisoxazolyl counterparts 79 and 80,
but their D3:D2 preference is attenuated. Thus, 84 is a nanomolar
(Ki =4.8 nM), but only weakly preferential D3 ligand (5.6-fold
vs. D2).
Employing click chemistry-based 1,3-dipolar cycloaddition to
synthesize a focused library of N-benzyl-1,2,3-triazole carbox-
amides has yielded a series of superior picomolar α1 ligands.
Some of these show also high D3 affinity. For instance the 1-(2-
bromo)benzyl-5-propyl-1,2,3-triazole-4-carboxamide 85 binds
with low nanomolar affinity to D3 receptors (Ki=3.5 nM) and
also with subnanomolar affinity (Ki=0.15 nM) to α1 receptors.
This very highα1 affinity appears to be related to the presence of a
2-methoxyphenylpiperazine moiety, as this picomolar affinity is
strongly impaired when changing to a 2,3-dichlorophenylpiper-
azine. The 1-benzyl-5-propyl-1,2,3-triazole-4-carboxamide deri-vative 86 for example bears a 2,3-dichloro substitution pattern at
the phenylpiperazine and binds with only 5.5 nM to α1, while it
preserves a low nanomolar binding to D3 receptors (Ki=2.4 nM).
Aiming to develop new atypical antipsychotics, RGH-1756
(87) has emerged from a series of 2-methoxyphenylpiperazines
[62,63]. Although it is rather uncommon in D3 receptor ligands,
the extended π1 moiety consisting of a 4-(6-imidazo[2,1-b]
thiazolyl)phenyl partial structure is attached to the butylene
spacer by an ether group instead of an amide, thus enlarging the
flexible spacer and shortening the conjugated π1-system on this
side. However, despite of the missing carboxamide the linear
extension of the π1-system to the other side yields a
subnanomolar D3 ligand (Ki =0.12 nM) with high affinity at
5-HT1A (Ki =0.96 nM) and α2C receptors (Ki =4.0 nM) and a
selectivity of at least 91-fold over α2A, D2L, 5-HT7, D2S, D5 and
D1 receptors [64]. In GTPγS binding assay 87 inhibits the
stimulatory effect of dopamine at human D3 receptors with
nanomolar potency (IC50=8.5 nM) [65]. RGH-1756 has been
radiolabeled using [11C]methyl triflate [66] and applied to
cynomolgus monkeys for PET imaging of the monkey brain
[64]. In a recent study on spatial learning performance of rats in
a water labyrinth test, RGH-1756 together with other D3
antagonists improved FG7142-induced learning deficits and
scopolamine-induced amnesia [67]. Thus, it has been concluded
that the cognition-enhancing effect of D3 antagonists may be
beneficial in the treatment of cognitive dysfunction associated
with several psychiatric disorders.
3.3.4. 3-Dimensional extensions of the π1 moiety
Proceeding beyond these two dimensional variations, the
thin, “single-layer” π1 system has very recently been extended
to the third dimension by introducing metallocene carboxa-
mides (Scheme 11) [49,68]. As these bilayered aromatic
systems are sterically quite demanding (Fig. 3), the high D3
affinities found for the ferrocene derivative 89 (FAUC 382;
Ki =0.64 nM) and the ruthenocene derivative 91 (Ki =0.84 nM)
indicate that the binding site of the D3 receptor tolerates rather
bulky systems such as these metallocene carboxamides quite
well. Both compounds also show high affinity for the D4
receptors (Ki =0.63 nM for 89 and Ki =0.60 nM for 91) and their
selectivities for D3 and D4 over D2 receptors are moderate (D3:
D2 selectivity=∼48-fold for 89 and ∼51-fold for 91, D4:D2
selectivity=∼49-fold for 89 and ∼72-fold for 91). Moreover,
both have moderate to high selectivities for D3 over α1 (∼114-
fold for 89 and ∼31-fold for 91), 5-HT1A (∼42-fold for 89 and
∼92-fold for 91), 5-HT2, and D1 (both >390-fold for 89 and
91). In mitogenesis assays 89 and 91 are both partial agonists
at D3 receptors with 28% (EC50= 3.5 nM) and 50%
(EC50=9.1 nM) relative maximal effect, respectively. Thus,
89 and 91 can be regarded as “fancy bioisosteres” of the
benzamides or naphthamides, showing a highly unusual mixed
subnanomolar D3/D4 binding profile. Their 2-methoxyphenyl-
piperazine analogs FAUC 378 (88) and FAUC 413 (90) exhibit
both an impaired D3 receptor binding (Ki =6.5 nM for 88 and
Ki =10 nM for 90), but the subnanomolar affinity of 89 and 91
for D4 receptors is retained or even further improved in 88 and
90 (Ki =0.52 nM for 88 and Ki =0.37 nM for 90). The
Scheme 11.
Fig. 3. Electrostatic potentials mapped onto the van der Waals surfaces of the followin
(as in BP 897), ferrocene (as in FAUC 378 and FAUC 382), ruthenocene (as in FAUC
structures were derived from X-ray data of suitable precursors. Electrostatic potential
Spartan. The distribution of charge on the molecular surfaces was visualized with M
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88 (D1/D4=2900 and D2/D4=210) and 90 (D1/D4=1900 and
D2/D4=320), while the preference for D4 over α1 receptors is
reduced to 19-fold for 88 and 15-fold for 90. It should be
noticed that FAUC 378 (88) binds to 5-HT1A receptors with a
subnanomolar Ki of 0.50 nM, thus representing a superpotent
mixed D4/5-HT1A ligand. In mitogenesis assay FAUC 378 is a
strong partial agonist (67% relative maximal effect, EC50=
0.55 nM), which nicely corresponds to the intrinsic activity
obtained from [35S]GTPγS binding (74% relative maximal
effect, EC50=2.5 nM). Remarkably, the ruthenocene carbox-
amide analog FAUC 413 (90) does not show appreciable 5-
HT1A affinity (Ki =20 nM) and thus has been classified as a
D4-selective ligand. Evaluation in mitogenesis assay shows a
potent partial agonist profile at D4 receptors (60% relative
maximal effect, EC50=1.2 nM), however [
35S]GTPγS binding
indicates almost full agonistic properties (94% relative
maximal effect, EC50=1.9 nM) of FAUC 413.
As an even more structurally challenging three-dimensional
extension of the π1 system, a series of [2.2]paracyclophanecar-
boxamide derivatives (92–94) has been synthesized [69]. To
investigate the structural effects of the planar chirality of [2.2]
paracyclophane, the pure enantiomers (R)-92 (FAUC 418) and
(S)-92 have been prepared and tested. Interestingly, the structural
difference caused by this planar chirality leads to an eudismic ratio
of more than 15 (Ki=3.0 nM for (S)-92 and Ki=0.19 nM for
(R)-92). To evaluate the sensitivity of the binding profiles
toward the substitution pattern of the phenyl substituent, the 2,3-
dichloro, 3-chloro-2-methoxy, and 2,3-difluoro analogs 93, 94,
and 95, respectively, have been synthesized. In contrast to the
metallocenes 88–91, D3 receptor binding considerably decreases
for all GPCRs when displacing the 2-methoxy group
(Ki=3.6 nM for 93 and 1.9 nM for 95). The structural hybrid
94 bearing an ortho positioned methoxy group and a chloro
atom in meta position displays an interesting binding pattern
with both high D3 affinity (Ki=0.46 nM) and considerable
selectivity over the potential anti-target α1 (Ki=80 nM).g N-methylcarboxamide fragments: benzo[b]furan (as in 31 and 32), naphthalene
413 and 91) or paracyclophane (as in FAUC 418 and 93–95). The metallocene
charges were calculated using the PM3(tm) Hamiltonian in the program package
OLCAD implemented in SYBYL 6.9.1.
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revealed an approximately neutral antagonism at the D3 receptor
[69]. This finding appears to be rather surprising, as it is
complementary to the group of metallocenes 88–91, where all
ligands had partial agonist properties, and differs from the group
of monolayered dopaminergics such as BP 897, FAUC 346 and
365, where the intrinsic activity strongly depends on the nature
of both the π1 system and the phenyl substituents.
Further extension of the π1 moiety was performed though
creation of a “chimera” of the benzofuranylcarboxamide 31 and
the paracyclophanecarboxamide FAUC 418 (92) resulting in the
1(4,7)benzofurano-4(1,4)benzenehexaphanyl-12-carboxamide
96 [69]. This shift of the bilayered paracyclophane to a more
distal position results in a 15- and 84-fold decrease of D3Schemeaffinity as compared to 31 and FAUC 418, respectively.
Consequently, 96 points out the limitations of enlarging π1.
3.3.5. Rigidization of the spacer
In addition to the modifications already presented concerning
the structure of the π1 or π2 moieties and the length of the spacer
connecting π1 and π2, another strategy towards establishing
novel D3 ligands is the introduction of rigid partial structures into
the highly flexible alkyl spacer (Scheme 12). Based on previous
studies indicating that the introduction of a cyclohexylethyl
spacer was capable of inducing high D3 affinity [70], the
butylene chain of the 8-methoxy-substituted 66 has been
replaced by this rigidized trans-cyclohexylethyl spacer and
its piperidine analog. This has been combined with the12.
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noquinolines. The (R)-enantiomer (99 and 100) turns out to be
slightly superior to the (S)-enantiomer (97 and 98) for both
rigidized spacers, however, the corresponding eudismic ratio is
just <2. Using a trans-cyclohexyl-ethyl spacer yields good D3
affinity (Ki =10 nM for 98 and 4.7 nM for 100) and high
selectivity versus D2 receptors (>1000-fold for 98 and >1800-
fold for 100). Exchange of the trans-cyclohexyl into a piperidine
causes a severe loss of D3 affinity (Ki =7200 nM for 97 and
4600 nM for 99) and D2:D3 selectivity (>3.5. for 97 and >11 for
99). In order to achieve a more suitable lipophilicity, heteroaro-
matic derivatives of the racemate of 98/100 have been prepared
(Scheme 13) [71]. “Placement” of an aza atom in different
positions of the naphthyl moiety yields a number of quinolinyl
and isoquinolinyl carboxamides. Only the quinoline-6-carbox-
amide shows D3 binding (Ki =9.7 nM) and selectivity over D2
receptors (460-fold) similar to the naphthyl lead structure.
Other rigid structural elements, such as an o-, m- or p-
xylenylene spacer (101–103) or a cis-octahydropentalen-2,5-
diyl spacer (104) integrated into the BP 897 scaffold [52] result
in low to moderate affinities only. This clearly demonstrates that
these spacers are hardly able to rigidize the bioactive
conformation of BP 897. However, an interesting rank order
is found for the D3 binding of the ligands 101–104. While the
o-xylenylene spacer has the most deleterious effect (750 nM),
the m-xylenylene is significantly better (100 nM) and the p-
xylenylene is the best of these three spacers (Ki =40 nM). Thus,
the most linear structural element is favored over the more bent
elements. Further supporting this observation, also the similarly
extended octahydropentalene spacer is found to have compar-
able D3 affinity (37 nM).
Introduction of a double or a triple bond into the butylene
spacer produces the trans-butenylene derivative 105, the cis-
butenylene derivative 106 and the butynylene derivative 107
[72]. While 107 shows a strong decrease in D3 affinity
(390 nM), both 105 and 106 have nanomolar D3 affinities
(1.3 nM and 4.9 nM). Combining the trans-butenylene spacer
with established π1 and π2 moieties generates partly rigidized
structures with considerable D3 affinities [46]. Both, the 4-
pyridin-2-yl-benzamide derivative 108 and the 2-benzothio-
phene carboxamide derivative 109, retain affinities at D3
receptors (Ki =0.70 nM for 108 and 1.1 nM for 109) which
almost match the affinities of their butylene analogs
(Ki =0.50 nM for 77 and for FAUC 365).Scheme 13.Taking advantage of the structure–activity information of
previously invented D3 ligands, novel rigidized FAUC 365
analogs have been designed facilitated by the predictivity of
ligand-based 3D-QSAR models. Introduction of a cyclohexyl
ring annelated to the piperazine gives the [(7S,9aS)-2-
(2,3-dichlorophenyl)octahydro-pyrido[1,2-a]pyrazine-7-yl]
ethyl analog (110) of FAUC 365. The specific stereochemistry of
the annelated system implies a bend conformation which might
be the reason for its weak to moderate D3 receptor binding
(Ki =140 nM). Replacement of the butylene by a cis-cyclohex-
ylene spacer (111) also induces a bend conformation, which may
explain that 111 shows a similar D3 affinity (Ki =120 nM) as 110.
Introduction of a trans-cyclohexylene spacer connecting the
benzo[b]thiophene-2-carboxamide to the 2,3-dichlorophenylpi-
perazine moiety allows for a stretched conformation of the
ligand (112), which exhibits a low nanomolar D3 affinity
(Ki =2.5 nM), a medium preference over D2 receptors (30-fold)
and a pronounced selectivity over D4 receptors (3200-fold).
4. Conclusion
Careful affinity, selectivity and potency “tuning” has resulted
in the development of a variety of agonists, partial agonist, and
neutral antagonists selective for the dopamine D3 receptor. Thus,
strong D3 affinities and potencies, considerable selectivities over
the other dopamine receptor subtypes, as well as adjusted
intrinsic activities have been achieved up to date. Selectivity
profiles towards other biogenic GPCRs and pharmacokinetic
properties such as bioavailability, blood–brain distribution
or drug clearance may represent further dimensions of ligand
optimization.
With such a broad variety of ligands available, elucidation of
the therapeutic impact of D3 receptors will most likely further
proceed during the forthcoming years. However, the successful
treatment of multifactorial CNS diseases might require drugs
with balanced receptor binding and efficacy profiles recogniz-
ing more than one molecular target. Thus, a paradigm shift from
“magic bullets”, which are aimed with optimizing selectivity at
a single target, towards “magic shotguns” that interact with an
optimized spectrum of several targets may be necessary [73].
Further challenges in D3 drug discovery may be to find
ligands that are able to discriminate between different functional
states of the D3 receptor, which appears to relate to the ability of
these receptors to couple to different G proteins. Moreover,
there is strong evidence for the ability of rhodopsin-like (type I)
G-protein coupled receptors to form homo- or heterodimers (or
even higher order oligomers) [74]. In the near future, it may be
possible for ligands to distinguish between these higher order
oligomerization states of the receptor, which may have an
impact on their clinical utility in the treatment of specific central
nervous systems diseases.
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